Cognition and Patients With Lung Cancer (NCT07160751) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Cognition and Patients With Lung Cancer
France90 participantsStarted 2026-01
Plain-language summary
Cognitive complaints in patients treated for cancer can impact their quality of life.
Studies show that these cognitive complaints may have multifactorial origins and appear at different stages of the care pathway.
In a population of patients treated for confirmed localized non-small cell lung cancer (NSCLC), this study aims to detect and monitor the onset of cognitive complaints over time.
The timing of the complaints during the treatment, the cognitive functions affected (memory, attention, concentration…), as well as the perceived intensity of the discomfort, will be examined.
The study also explores the influence of co-factors such as mood, fatigue, socio-cultural status, and level of social vulnerability on these cognitive complaints.
Who can participate
Age range
18 Years – 74 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patient aged 18 to 74 years
* Suspected or confirmed localized and operable non-small cell lung cancer (NSCLC)
* Surgical treatment with or without perioperative systemic medical therapy
* Ability to independently complete self-questionnaires via the Cleanweb platform
* Patients with access to a phone, tablet, or computer at home to complete the electronic self-questionnaires.
Exclusion Criteria:
* Known pre-existing cognitive disorders
* Presence on the day of inclusion of one or more factors causing mental confusion: electrolyte imbalances, renal failure, hepatic failure, infections, bladder distension, fecal impaction
* Known psychiatric or neurological diseases (e.g., multiple sclerosis, Parkinson's disease, dementia, stroke, traumatic brain injury with loss of consciousness)
* Current use of neuroleptic treatments
* History of cancer treatment within the past 10 years
* Fibromyalgia
* Individuals who cannot read French or are not French-speaking
* Patients who have never attended school
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To examine the onset, intensity and duration of the PCI (Perceived Cognitive Impairment) score